New medicines
NICE recommends baricitinib as an option for treating moderate to severe atopic dermatitis in adults. PBR excluded high cost drug, for specialist use only.
NICE recommends filgotinib as an option for treating active moderate to severe RA in adults. PBR excluded high cost drug, for specialist use only.
NICE recommends dapagliflozin as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults. Prescribing and monitoring of dapagliflozin must be retained by the heart failure specialist until the patient’s heart failure regimen and, for diabetic patients, their diabetes regimen, are considered stable. The specialist can then request that the GP continues prescribing.
Not recommended until NICE TA published.
Not recommended until NICE TA published.
Not recommended until NICE TA published.
Not recommended until NICE TA published
Formulary and Guidelines
Addition of subcutaneous formulation to formulary in addition to intravenous formulation. No significant cost impact.
Addition of subcutaneous formulation to formulary in addition to intravenous formulation. No significant cost impact.
Statement updated to include Freestyle Libre 2 upgraded version of flash glucose monitoring sensors. Cost identical to original Freestyle Libre sensors
NHSE Accelerated Access Collaborative document - Pan Mersey endorsement of the document and addition of link to the document from the APC website.
NHSE Accelerated Access Collaborative document - Pan Mersey endorsement of the document and addition of link to the document from the APC website.
Shared Care
Additional bullet point to be added to the Primary Care Responsibilities section in Appendix 1 of the shared care frameworks.
|
